✦ LIBER ✦

Advances in the epidemiology of Alzheimer's disease: will empiricism improve the public's health?

✍ Scribed by Gary J. Kennedy

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 37 KB
Volume: 16
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.556

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advances in the drug treatment of Alzhei

Advances in the drug treatment of Alzheimer's Disease

✍ B. E. Leonard 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

There are two main approaches to the treatment of Alzheimer's disease. The ®rst approach is to prevent the neurodegenerative changes that ultimately cause irreversible damage to the brain. As the excessive formation of betaamyloid protein appears to play a primary role in the neurodegenerative proce

Assessment of health economics in Alzhei

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK

✍ A. Ward; J. J. Caro; D. Getsios; K. Ishak; J. O'Brien; R. Bullock 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

## Abstract ## Objective To assess the long‐term health and economic impact of treating mild to moderate Alzheimer's disease (AD) with galantamine (16 mg or 24 mg per day) compared to no cholinesterase therapy in the UK. ## Methods The long‐term costs and outcomes were assessed using a model dev

Assessing the relationship between healt

Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease

✍ Edward Alan Miller; Lon S. Schneider; Robert A. Rosenheck 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

## Abstract ## Objectives To examine the relationship between use of multiple health services and health utilities, quality of life and other factors in Alzheimer's disease (AD). ## Design Data were obtained via caregiver proxy at baseline and 3‐ 6‐ and 9‐months post‐random assignment among 421

Improved survival in the treatment of ad

Improved survival in the treatment of advanced hodgkin's disease at a nonuniversity institution (1970–1979)

✍ William R. Friedenberg; P. Dirks; E. Beltaos; J. J. Mazza; J. L. Hoehn; R. H. Gr 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 469 KB 👁 2 views

From 1970 through 1979, 89 patients with Hodgkin's disease were treated at the Marshfield Clinic/St. Joseph's Hospital. After the pathologic material was reviewed, the patients were analyzed to compare Group I (1970-1973) with Group I1 (1974)(1975)(1976)(1977)(1978)(1979). Demographic characteristic

Alzheimer's disease in the UK: comparati

Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding

✍ Ana Lowin; Martin Knapp; Paul McCrone 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## Objective To review the economic cost of Alzheimer's disease, to determine the level of research expenditure directed at this illness and to make comparisons with cancer, stroke and heart disease. ## Method A literature search of cost‐of‐illness studies was conducted and major fun

R-flurbiprofen improves axonal transport

R-flurbiprofen improves axonal transport in the Tg2576 mouse model of Alzheimer's Disease as determined by MEMRI

✍ Karen D. B. Smith; Richard Paylor; Robia G. Pautler 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB

Axonal pathology is a prevalent feature of Alzheimer's disease (AD) and is thought to occur predominantly due to the accumulation of amyloid beta (Aβ). However, it remains unclear whether therapeutics geared toward reducing Aβ improves axonal deficits. We have previously used Manganese Enhanced MRI